Home/Pipeline/Beta-lactam API Portfolio

Beta-lactam API Portfolio

Bacterial Infections

CommercialMarketed

Key Facts

Indication

Bacterial Infections

Phase

Commercial

Status

Marketed

Company

Nectar Lifesciences

About Nectar Lifesciences

Nectar Lifesciences operates a dual-strategy business model, combining a legacy, low-margin API manufacturing operation with a high-growth, direct-to-patient clinical services segment. Founded in 1995, the company has achieved significant scale with a $1.81B valuation, driven by its vertically integrated manufacturing capabilities and regulatory approvals from the US FDA and UK MHRA. Its strategic pivot into the US allergy care market represents a bold move to capture higher margins and recurring revenue from a large, underserved patient population, though it creates a unique and complex corporate profile.

View full company profile

Therapeutic Areas

Anti-infectives Allergy & Immunology Cardiology Gastroenterology Pain Management

Other Bacterial Infections Drugs

Drug	Company	Phase	Status
Generic Portfolio Expansion - Anti-infectives	Alkaloid AD Skopje	Regulatory Submission	Active
Vibativ® (telavancin)	Cleo Life Sciences	Approved	Supported late-stage development & NDA
Penicillin V API	Biotika	Commercial	Active
Sterile Injectable Antibiotics Portfolio	Steripharma	Approved	Active
Oral Antibiotic	Dawah Pharmaceuticals	ANDA Filed/Pre-approval	Active
XAB05/XAB06	Xenothera	Preclinical	Active
Antibacterial Program	Prosetta Biosciences	Preclinical	Active
Novel Antibiotic Class 1	ArrePath	Pre-clinical	Active
Novel Antibiotic Class 2	ArrePath	Pre-clinical	Active
Amoxicillin/AmoxiClav Generics	Puren Pharmaceuticals	Approved	Active
Ready-to-Use Antibiotics in Bags	Galenica Senese	Commercial	Active
Lasvic (Lascufloxacin)	KYORIN Pharmaceutical	Marketed	Active